Cargando…
The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal Late-Stage T Cells
Adoptive therapy of malignant diseases with tumor-specific cytotoxic T cells showed remarkable efficacy in recent trials. Repetitive T cell receptor (TCR) engagement of target antigen, however, inevitably ends up in hypo-responsive cells with terminally differentiated KLRG-1(+) CD57(+) CD7(−) phenot...
Autores principales: | Rappl, Gunter, Riet, Tobias, Awerkiew, Sabine, Schmidt, Annette, Hombach, Andreas A., Pfister, Herbert, Abken, Hinrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264628/ https://www.ncbi.nlm.nih.gov/pubmed/22292024 http://dx.doi.org/10.1371/journal.pone.0030713 |
Ejemplares similares
-
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle
por: Hombach, Andreas A., et al.
Publicado: (2013) -
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013) -
Chimeric antigen receptors designed to overcome transforming growth factor‐β‐mediated repression in the adoptive T‐cell therapy of solid tumors
por: Hartley, Jordan, et al.
Publicado: (2019) -
IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors
por: Hombach, Andreas, et al.
Publicado: (2022) -
Most Do, but Some Do Not: CD4(+)CD25(−) T Cells, but Not CD4(+)CD25(+) Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)
por: Hombach, Andreas A., et al.
Publicado: (2017)